Polsinelli shareholder Aaron E. Zerykier has entered an appearance for clinical stage drug developer Humanigen Inc. and its top officers in a pending securities class action. The case, filed Aug. 26 in New Jersey District Court by Pomerantz LLP and Bronstein, Gewirtz & Grossman, accuses the defendants of overhyping the potential that its lead product candidate, lenzilumab, would be approved as a treatment for COVID-19. The case, assigned to U.S. District Judge William J. Martini, is 2:22-cv-05258, Pieroni v. Humanigen, Inc. et al.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]